Profile data is unavailable for this security.
About the company
Pfizer Inc. is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products around the world. The Company operates through two segments: Biopharma and PC1. Biopharma is engaged in the science-based biopharmaceutical business. PC1 is its global contract development and manufacturing organization and supplier of specialty active pharmaceutical ingredients. The Company’s primary care products include Eliquis, Nurtec ODT/Vydura and the Premarin family; the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac and Trumenba; Comirnaty, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Eucrisa/Staquis and Cibinqo; the Vyndaqel family, Oxbryta, BeneFIX and Genotropin, and Sulperazon, Medrol, Zavicefta, Zithromax, Vfend and Panzyga. Its oncology products include Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena and Braftovi.
- Revenue in USD (TTM)92.95bn
- Net income in USD29.04bn
- Incorporated1942
- Employees83.00k
- LocationPfizer Inc66 HUDSON BOULEVARD EASTNEW YORK 10001-2192United StatesUSA
- Phone+1 (212) 733-2323
- Fax+1 (302) 655-5049
- Websitehttps://www.pfizer.com/
Mergers & acquisitions
| Acquired company | PFE:NYQ since announced | Transaction value |
|---|---|---|
| Lucira Health Inc | -7.68% | 22.40m |
| Seagen Inc | -2.61% | 43.84bn |
| Global Blood Therapeutics Inc | -22.14% | 5.07bn |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amgen, Inc. | 26.19bn | 7.92bn | 116.52bn | 25.20k | 14.81 | 21.79 | 10.23 | 4.45 | 14.72 | 14.72 | 48.70 | 10.01 | 0.3541 | 1.39 | 4.84 | 1,039,286.00 | 10.70 | 11.14 | 13.11 | 13.81 | 75.08 | 77.99 | 30.23 | 28.79 | 2.79 | 5.88 | 0.9201 | 53.53 | 1.32 | 2.87 | 11.18 | -4.10 | 7.11 | 11.03 |
| Bristol-Myers Squibb Co | 45.85bn | 7.31bn | 137.94bn | 34.30k | 19.13 | 4.33 | 7.90 | 3.01 | 3.43 | 3.43 | 21.49 | 15.15 | 0.4647 | 4.32 | 5.91 | 1,336,676.00 | 7.43 | 2.80 | 9.44 | 3.45 | 77.82 | 75.49 | 15.99 | 6.98 | 1.28 | 9.52 | 0.5426 | 148.90 | -0.4872 | 17.31 | -9.54 | 10.14 | 1.17 | 6.72 |
| Pfizer Inc. | 92.95bn | 29.04bn | 216.55bn | 83.00k | 7.56 | 2.14 | 6.29 | 2.33 | 5.07 | 5.08 | 16.23 | 17.89 | 0.4899 | 3.03 | 7.28 | 1,119,904.00 | 15.33 | 8.77 | 19.19 | 11.07 | 68.15 | 70.32 | 31.28 | 24.35 | 1.11 | 26.12 | 0.2617 | 57.53 | 23.43 | 13.81 | 39.95 | 21.38 | 7.86 | 4.56 |
| AbbVie Inc | 56.74bn | 7.53bn | 241.48bn | 50.00k | 32.29 | 18.19 | 14.93 | 4.26 | 4.24 | 4.24 | 31.93 | 7.53 | 0.4086 | 4.50 | 5.11 | 1,134,820.00 | 5.47 | 7.57 | 6.98 | 9.68 | 70.96 | 71.58 | 13.38 | 18.43 | 0.8211 | 8.96 | 0.8236 | 97.86 | 3.30 | 15.52 | 2.74 | 15.70 | 5.61 | 17.11 |
| Merck & Co Inc | 57.87bn | 13.03bn | 285.51bn | 69.00k | 21.96 | 6.10 | 16.91 | 4.93 | 5.12 | 5.12 | 22.76 | 18.46 | 0.5397 | 2.71 | 5.72 | 838,681.20 | 12.17 | 9.40 | 15.45 | 12.60 | 72.75 | 71.35 | 22.54 | 18.84 | 1.19 | 18.09 | 0.396 | 71.79 | 21.72 | 8.12 | 17.61 | 23.67 | 18.37 | 3.48 |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2023 | 484.03m | 8.61% |
| BlackRock Fund Advisorsas of 31 Mar 2023 | 295.95m | 5.27% |
| SSgA Funds Management, Inc.as of 31 Mar 2023 | 281.83m | 5.02% |
| Capital Research & Management Co. (World Investors)as of 31 Mar 2023 | 231.51m | 4.12% |
| Wellington Management Co. LLPas of 31 Mar 2023 | 218.93m | 3.90% |
| Geode Capital Management LLCas of 31 Mar 2023 | 109.85m | 1.96% |
| Charles Schwab Investment Management, Inc.as of 31 Mar 2023 | 83.90m | 1.49% |
| Norges Bank Investment Managementas of 31 Dec 2022 | 61.48m | 1.09% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2023 | 59.01m | 1.05% |
| Capital Research & Management Co. (International Investors)as of 31 Mar 2023 | 56.00m | 1.00% |
